Xencor Quarterly Income Statement
NASDAQ: XNCRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xencor revenue and earnings
In the quarter ended Jun 30, 2026, Xencor generated $51.2 million in revenue, up 17.5% from the same quarter a year earlier. Xencor reported a net loss of $21.7 million, compared with a loss of $30.8 million a year earlier. Operating margin was -72.4%.
Diluted earnings per share came in at -$0.29.
Summary generated from market data by MetaCap's automated system. Methodology
Xencor income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.22M | 4.52M | 28.24M | 21.00M | 43.61M | 32.73M | 52.79M | 17.80M | 23.91M | 16.00M | 50.97M | 59.16M |
| Revenue growth (YoY) | +17.46% | -86.20% | -46.51% | +18.00% | +82.41% | +104.61% | +3.58% | -69.92% | -47.48% | -15.64% | +135.84% | +116.73% |
| Operating Expenses | 88.29M | 82.38M | 81.86M | 68.52M | 76.78M | 75.92M | 65.97M | 72.99M | 79.28M | 70.66M | 78.32M | 77.43M |
| Research & Development | 71.91M | 64.67M | 64.82M | 54.37M | 61.66M | 58.58M | 51.06M | 58.23M | 61.53M | 56.87M | 63.05M | 64.94M |
| Operating Income | -37.07M | -77.86M | -53.63M | -47.52M | -33.17M | -43.18M | -13.18M | -55.20M | -55.37M | -54.66M | -27.35M | -18.27M |
| Interest Expense | 7.35M | 4.70M | 7.35M | 7.67M | 8.24M | 8.66M | 8.66M | 9.03M | 9.28M | 9.68M | 6.16M | 7.00K |
| Other Income (Expense) | 15.15M | -50.77M | 49.36M | 41.49M | 2.10M | -5.08M | -31.41M | 7.75M | -13.41M | -19.45M | 14.70M | -6.00M |
| Pretax Income | -21.92M | -128.64M | -4.27M | -6.03M | -31.07M | -48.27M | -44.58M | -47.44M | -68.78M | -74.12M | -12.65M | -24.27M |
| Income Tax | -190.00K | 280.00K | 2.39M | 0 | -250.00K | 367.00K | 1.62M | 0 | 0 | 0 | 13.66M | 0 |
| Net Income | -21.73M | -128.92M | -6.65M | -6.03M | -30.82M | -48.42M | -45.55M | -46.29M | -67.34M | -73.44M | -26.15M | -24.27M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.29 | -1.71 | -0.09 | -0.08 | -0.41 | -0.66 | -0.57 | -0.72 | -1.09 | -1.20 | -0.41 | -0.40 |
| EPS (Diluted) | -0.29 | -1.71 | -0.09 | -0.08 | -0.41 | -0.66 | -0.57 | -0.72 | -1.09 | -1.20 | -0.41 | -0.40 |
| Shares Outstanding (Basic) | 75.86M | 75.25M | — | 74.41M | 74.28M | 73.67M | — | 64.02M | 61.68M | 61.21M | — | 60.62M |
| Shares Outstanding (Diluted) | 75.86M | 75.25M | — | 74.41M | 74.28M | 73.67M | — | 64.02M | 61.68M | 61.21M | — | 60.62M |
| EBITDA | -34.63M | -75.30M | -51.05M | -44.93M | -30.52M | -40.49M | -10.18M | -52.14M | -52.35M | -51.63M | -24.12M | -15.13M |
| Operating Margin | -72.37% | -1724.14% | -189.92% | -226.29% | -76.07% | -131.93% | -24.96% | -310.17% | -231.61% | -341.71% | -53.67% | -30.88% |
| Net Margin | -42.42% | -2854.65% | -23.56% | -28.70% | -70.69% | -147.92% | -86.29% | -260.10% | -281.66% | -459.09% | -51.30% | -41.02% |
This table shows 12 quarterly periods of Xencor's income statement, from Q2 2026 back to Q3 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow XNCR's reporting calendar. What is a income statement?